nuwellis®

Investor Presentation

March 2024

Safe Harbor Statement

Forward Looking Statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the future that are intended to be covered by the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, all forward-looking statements are management's present expectations and are not guarantees of future events and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "could," "would," "should," "plan," "predict," "potential," "project," "promising," "expect," "estimate," "anticipate," "intend," "goal," "strategy," "milestone," and similar expressions and variations thereof. Various factors could cause actual results to differ materially from these statements including our ability to execute on our commercial strategy and to grow our Aquadex® business, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our expectations regarding anticipated synergies with and benefits of the Aquadex business, our business strategy, market size, potential growth opportunities and the other risks set forth under the caption "Risk Factors" and elsewhere in our periodic and other reports filed with the U.S. Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent reports. We are providing this information as of the date of this presentation, and we undertake no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Although the Company believes that the forward-looking statements are reasonable and based on information currently available, it can give no assurances that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Financial and Statistical Data

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. These data involve a number of assumptions and limitations and have not been reviewed or audited by our independent registered accounting firm. You are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Neither we nor our advisors or representatives makes any representations as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation.

Trademarks

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

Additional Information

You should read the documents that we have filed with the SEC for more complete information about us. We encourage you to read such documents in full for more detailed information, statistics, reports and clinical trials referenced in this presentation. You may access these documents for free by visiting EDGAR on the SEC website at http://www.sec.gov.

nuwellis®

Overview

- The Problem: Fluid Overload
- The Market Opportunity
- Nuwellis Solutions
- Market Validation
- Growth Strategy
- Financial Snapshot
- Team

Our Mission

Nuwellis is dedicated to transforming the lives of patients suffering from Fluid Overload through science, collaboration, and innovation.

The Problem

Fluid Overload presents a significant public health challenge that impacts both patient outcomes and hospital resources.

nuwellis®

What is Hypervolemia (Fluid Overload)?

Hypervolemia is an excess of fluid in the bloodstream, vital organs and interstitial space that results in an array of patient symptoms



nuwellis®

6.7 million US adults with Heart Failure and ~50% will die within five years of their diagnosis[5,6]

With Fluid Overload as a leading cause of HF readmissions, it also presents a considerable economic burden on hospitals

PATIENT	HOSPITAL

• Over 1 million HF hospitalizations occur annually in the US[1]
• Efficacy of diuretic use in HF & CV surgery patients
  • 10-40%[4] are refractory
  • 68%[4] show sub-optimal response
	• Non-reimbursed 30-day readmissions can cost up to $15.2M annually[2]
	• High readmission rates lead to Medicare penalties[3]

The Healthcare Burden of Heart Failure/Fluid Overload

90% of Heart Failure (HF) hospitalizations are due to signs and symptoms of Fluid Overload[1]

- **Unresolved congestion**
- **Poor clinical outcomes**[1]

Long Lengths of Stay & High Costs of Care

8.3 Days
Average HF Length of Stay[2]

$24,027
Total True Inpatient Cost per Encounter[2]

High Readmission Rates

24%
30-Day Readmission rate[1]

44%
6-months Readmission rate[1]

Related Costs/Penalties

$24,027
HF hospitalization cost[2], of which only 34% will typically be covered by reimbursement[7]

Opportunity Cost of occupied bed
Up to 3%
of ALL Medicare reimbursements[3]

1. Costanzo MR, et al. *J Am Coll Cardiol*. 2017 May 16;69(19):2428-2445. 2. From Premier Applied Sciences database. 3. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program 4. Testani, Circ Heart Failure, 2016;9:e002370. 5. Shah, K, et al. J Am Coll Cardiol. 2017 Nov, 70 (20) 2476–2486. 6. Bozhurt B, et al. J Card Fail. J Card Fail. 2023; 2910): 1412-42. 7. Reimbursement estimates from MCRA.

nuwellis

The market faces an urgent challenge as three patient categories grapple with the debilitating impact of Fluid Overload across multiple hospital specialty units

Fluid Overload is **the leading cause of hospital readmission** post 30 days following cardiac surgery[2]

Heart Failure

90% of all heart failure hospitalizations are due to symptoms of Fluid Overload [1]

Critical Care

Fluid Overload is the **leading cause of death** for critically ill patients in the ICU within 90 days[3]

Pediatric

In pediatric patients, Fluid Overload is associated with **significant increases in mortality**[4-5]

1. Costanzo MR, et al. JACC. 2017 May 16;69(19):2428-2445. 2. Iribarne A, et al. Ann Thorac Surg. 2014; 98(4): 1274-80. 3. Vaara ST et al. Crit Care.2012; 16: 1-11. 4. Sutherland SM, et al. Am J Kidney Disease. 2010; 5(2): 316-25. 5. Gillespie RS, et al. Ped Nephro. 2004; 19(12): 1394-99.

nuwellis®

Diuretics, the current standard of care, have significant limitations leaving a gap in clinical care

Diuretics provide insufficient symptom relief and are **associated with in hospital worsening heart failure** and **increased mortality** after discharge[1]

- High risk of readmissions [1]
- Long-term use of diuretics is associated with kidney damage[1-4]
- Efficacy of diuretic use in HF & CV surgery patients
  - 10-40%[5] have poor diuretic response
  - 68%[5] show sub-optimal response

"Diuretic resistance has been a well-known challenge in the care of these patients, and not surprisingly is tied to worse prognosis."[6]

"Extracorporeal Ultrafiltration for Acute Heart Failure"
Cardiorenal Medicine Journal

1. Costanzo MR, et al. *JACC*. 2017;69(19)2428-2445. 2. Felker MG & Mentz RJ. *JACC*. 2012;59(24):2145-53. 3. Al-Naher et al. *Br J Clin Pharmacol*. 2018 Jan; 84(1): 5–17. 4. Butler J et al. *Am Heart J*. 2004 Feb;147(2):331-8. 5. Testani JM, et al. *Circ Heart Fail*. 2016;9(1):e002370. 6. Kazory et al. Cardiorenal Med 2023;13:1-8. doi: 10.1159/000527204.

nuwellis

Market Opportunity

Across our three strategic patient categories, we have an enormous opportunity to improve outcomes for Fluid Overload patients across multiple hospital specialty units.

nuwellis®

With a large and expanding addressable market, Nuwellis stands at the forefront of a transformative healthcare opportunity

Outpatient market opportunity adds $0.5B+ to addressable market (heart failure and advanced liver disease)

$2B+ TAM

Heart Failure

$1B Market[1]

~30% of current sales

Critical Care

$900M Market[1]

~40% of current sales

Pediatric

$130M Market[1]

~30% of current sales

1. See Appendix.
2. Approved for use in pediatric patients weighing 20 kg or more.

nuwellis®

Differentiated Solutions

Nuwellis is a different company today

Aquadex represent our foundation, positioning the company to effectively address significant market opportunities

Robust clinical foundation reinforces strategic technology expansion and collaboration

nuwellis®

Products

aquadex SmartFlow®

Vivian

Patent Portfolio

- Console
- Circuit
- Peripheral Access
- Accuracy & Safety
- Guided Therapy

Collaborations

SeaStar Medical

DaVita

Our hero therapy:

Aquadex®

A clinically superior solution for Fluid Overload

The *only* device of its kind in the market

How the Aquadex system works

Predictable and precise fluid removal



1 Blood is taken from the patient via the withdrawal line using proprietary catheters technology

2 The blood is pushed through the filter by the blood pump

(0-40 ml per minute)

3 The ultrafiltration pump withdraws fluid across filter membrane using negative pressure

Hematocrit sensor monitors preset hematocrit limits



4 Ultrafiltration pump can pull 0-500 ml of fluid per hour

5 Filtered blood returns to the patient via the infusion line

nuwellis

At a Recent Late Breaking Clinical Trials, Significant Reduction in HF Events and HF Hospitalization

Present at THT 2024 in early March, a re-appraisal of a 224-patients control randomized trial (AVOID-HF) demonstrated significant statistical significance



Number at risk:

AQ	105	98	94	88
LD	108	100	91	81



Number at risk:

AQ	105	98	94	88
LD	108	102	92	83

THT Boston 2024 – Featured Late-Breaking Clinical Science Abstract III – Aquapheresis for Management of Decompensated Heart Failure: A Re-appraisal of AVOID-HF

Aquadex

A proven and predictable solution for Fluid Overload.

81%[1] hospitalization reduction
Compared to diuretics

48% lower readmission
than the national average at 30 days[1]

$3,975 in average savings
Reduces length of hospital stay when initiated early, resulting in average savings of $3,975 (14%)[6-7]

Over $2B addressable market

Reintroduced in 2016

- An estimated 25,700 patients treated across all three of our customer categories[9]
- From proprietary technology to unmatched advantages in Fluid Overload therapy, Aquadex has the potential to be the standard of care for diuretic resistant patients

Product Strategy & Differentiation

- More effective in decongesting resulting in stabilized or improved cardiac hemodynamics[2-5]
- Easier to set-up than CRRT; built-in Hematocrit sensor allows real-time measurement of blood volume changes
- Designed for multiple settings: ICU, Stepdown Unit, Telemetry Unit, HF Floor, and Outpatient – versus ICU only for CRRT
- Predictably removes excess isotonic fluid (water and sodium)[8]
- No significant changes to kidney function[1]

1. Watson R et al. *J Cardiac Fail*. 2020; 26(10): s56. 2. Kiziltepe, U, et al. *Ann Thorac Surg*. 2001;71(2): 684-93. 3. Sahoo, TK, et al. Indian J Thorac Cardiovas Surg. 2007;23(2): 116-24. 4. Boga et al. *Perfusion*. 2000;15:143-50. 5. Onoe et al. *Perfusion*. 2001;16:37-42.65. 6. Costanzo MR et al. *JACC*. 2005; 46(11); 2457-51. 7. Costanzo, et. al., ISPOR 23rd Annual Int'l Mtg., May 19-23, 2018, Baltimore, MD, USA. 8. Kazory A, Sgarabotto L, Ronco C: Extracorporeal Ultrafiltration for Acute Heart Failure. Cardiorenal Med 2023;13:1-8. doi: 10.1159/000527204. 9. Utilization figures are based upon Company estimates, including certain good faith assumptions of the number of blood circuits used per adult and per pediatric procedures, such that patients served equals total number of units sold divided by a per procedure estimate of circuit used per adult and pediatric patients.

Coming soon:

Vivian™

Our pediatric solution

On track for H1 2025 launch



We've seen a steady increase in our pediatric business, providing patients with high mortality an opportunity at life[1]

Pediatrics represents a $130M TAM



4-10 circuits/pts

3-6 consoles per hospital

Received 510(k) and launched commercially in Q1 2020.

Improved patient survival at end of treatment

Attributes	Group 1: <10kg	Group 2: 10-20kg	Group 3: >20kg
# of Patients	N = 72	N = 13	N = 34
Primary disease	43% kidney 29% cardiac	54% kidney 31% other	38% kidney 28% cardiac
Survival at end of treatment (Aquadex)	43 **(60%)**	13 **(100%)**	33 **(97%)**

Group 1 patients traditionally do not receive any kind of therapy

"For our babies born with diseased or absent kidneys, Aquadex has given them a chance at life because in the past, there were no options to treat these patients."

Kara Short
MSN, CRNP, NICU nurse practitioner at Alabama Children's Hospital

1. Source: Menon S, et al. CJSN, 2019; 14: 1432-40. Aquadex is currently cleared for use in pediatric patients weighing 20 kg or more.

nuwellis

Introducing Vivian™

Therapy to fill crucial gaps, offering a lifeline to critically ill neonates and children

Ultrafiltration
Hemofiltration
Hemodialysis

8.5x mortality

Fluid Overload drives pediatric morbidity and mortality risk in critically ill patients

Children with >20% fluid overload had an odds ratio for mortality of 8.5 compared to children with <20% FO [1,2]

60% survival to end therapy

Providing renal support and hemodynamic stability can be life-saving

In patients <20 kg who primarily received Slow Continuous Ultrafiltration (SCUF)[3]

$130m addressable pediatric market

Launch best-in-class pediatric CRRT system, 1H 2025

- Early feedback from pediatric nephrologists: "This will be a game-changer for us." Nuwellis Pediatric Advisory Board member

Product Strategy & Differentiation

- Integrates Ultrafiltration with Hemofiltration and Hemodialysis capabilities
- Expected broadest weight indication: 2.5 kg +
- Safety features: lowest extracorporeal blood volume; built-in hematocrit sensor
- Clinician-driven UX design
- Product name: "Viv" Latin root means life; Vivian – Lady of the Lake in King Arthur, allusion to Land of 10,000 Lakes

1. Sutherland SM, et al. American Journal of Kidney Diseases, vol. 55, no. 2, pp. 316-325, February 2010, 2. Gillespie RS, et al. Pediatric Nephrology, vol. 19, no. 12, pp. 1394-1399, December 2004., 3. Menon S, et al. CJSAN, vol 14, October 2019.

nuwellis

We are keenly focused on developing novel technology with a strong IP portfolio

16 novel patents with protection to 2043+

- Robust and evolving portfolio of patents circling the technology
- 20 Nuwellis patent applications (US & EU) in addition to licensed IP from Baxter
- 1 pending patent application, expected to issue January 9, 2024
- Wide technology scope coverage

Console	Circuit	Peripheral Access	Accuracy & Safety	Guided Therapy
Transport Mode	Filter Clotting Prevention	Peripheral Flow Improvements	External Pump Detection	Plasma and Blood Volume Measurement
Self-loading/ Self-emptying Bags	Source Line Connection	Dual Lumen Catheter	Hemolysis/ Blood Leak Detector	Physiological Parameters Guidance
Open vs. Closed Loop			Accounting for Density	
			Auto Clamp	

Strategic Collaborations

Our collaborations with DaVita and SeaStar are expanding market access, bolstering technology offerings, and accelerating Nuwellis growth trajectory.

In June of 2023, we launched a supply and collaboration agreement with DaVita to expand the access of Aquadex therapy for heart failure

900+ hospital partnerships[1]

2,500+ clinic[1]

6,500+ employees[1]

11.6B in revenue in 2022[1]

1. Used with permission from DaVita

SeaStar distribution and licensing agreement to offers a new Selective Cytopheretic Device (SCD-PED) for pediatric patients with AKI

77% mortality reduction[1]
At day 60

NO dialysis dependency[2]
At day 60

2x length of stay in ICU for patients with AKI
(8 days vs. 4 days) as ICU patients without AKI[3]

1) Use of the Selective Cytopheretic Device to Support Critically Ill Children Requiring Continuous Renal Replacement Therapy: A Probable Benefit-Risk Assessment Stuart L. Goldstein, Nicholas J. Ollberding, David J. Askenazi, Rajit K. Basu, David T. Selewski, Kelli . Krallman, Lenar Yessayan, H. David HumesmedRxiv 2023.08.22.23294378; doi: https://doi.org/10.1101/2023.08.22.23294378 **2)** SL Goldstein et al.: The Selective Cytopheretic Device in Children; Kidney International Reports (2021) **3)** De Zan F, Amigoni A, Pozzato R, Pettenazzo A, Murer L, Vidal E. Acute Kidney Injury in Critically Ill Children: A Retrospective Analysis of Risk Factors. Blood Purif. 2020;49(1-2):1-7. doi: 10.1159/000502081. Epub 2019 Aug 5. PMID: 31382259.

Financial Snapshot
Key Milestones
Executive Team
Investment Highlights

nuwellis®

With a track record of consistent financial success, we're confident that our growth strategy will lead to meaningful revenue expansion

Annual Revenue ($000)



CASH
$3.8 million as of Dec 31, 2023

NO DEBT

Common Shares Outstanding	**6,801,443**
Common Share Equivalents:	
Preferred Shares:	
Preferred F: 127 units - $1.01 per common share	125,857
Preferred J: 82 units - $1.01 per common share	2,029
Warrants:	
Historical Warrants	17,749
Preferred J Warrants: 67,168 units - $1.01 per common share	831,287
DaVita Warrants*: 1,289,081 units - $3.30 per common share	1,289,081
Employee & Director Options:	
Options Issued & Outstanding	151,935
Total Common Share Equivalents	**2,417,938**
Total Common Share & Share Equivalents	**9,219,381**

*DaVita warrants are milestone based split between 4 tranches. No milestones achieved to date.

Capitalization Table as of March 1st, 2024

nuwellis

Our 2023 quarterly results reflect improving operational efficiencies

We've increased revenue and become more efficient in spend, resulting in a decrease in operating loss

($000)





Unaudited *

nuwellis

Key milestones



nuwellis

Our diverse leadership team boasts extensive industry experience and a successful history of commercialization

Nestor Jaramillo, Jr.
President & Chief Executive Officer

Rob Scott
Chief Financial Officer

Megan Catts
Vice President of Clinical Research and Reimbursement

John Kowalczyk
Senior Vice President of Sales & Marketing

John Jefferies, M.D.
Chief Medical Officer

Seasoned Leadership: Over 200 years' collective experience in clinical practice and the medical device industry, with significant tenures at industry leaders such as Medtronic, Boston Scientific, and Abbott/St. Jude Medical.

Commercialization Prowess: Demonstrated success in commercializing various therapies, showcasing the team's ability to bring innovative medical devices to market effectively.

Strategic Industry Involvement: In-depth industry knowledge and strategic insights gained from working with major players in the medical device sector.

Adaptive Management: Dynamic management style with a history of successfully navigating challenges and adapting to evolving market dynamics.

Innovative Contribution: Track record of contributing to the growth and success of previous ventures through innovation and product development.

nuwellis

Investment Highlights

We're confident that the key catalysts we will pursue in 2024 should support a valuation of 3-5x revenue.

$2B+ TAM	Positive ROI	Clinical Evidence	Scalable Consumables	Commercial Infrastructure	Product Pipeline	Leadership Team
$2B+ and growing addressable market in critical need	Attractive clinical + economic benefits to hospitals and healthcare system	Robust body of clinical evidence demonstrating the success of our products	Scalable consumables driven growth	Commercial infrastructure leverage	Novel product pipeline along with an expanding IP Portfolio for continued expansion	Highly experienced leadership perfectly positioned to drive our growth strategy

nuwellis®

Thank you!

Appendix

DaVita pilot to commercialization

In June of 2023, we launched a supply and collaboration agreement with DaVita to expand the access of Aquadex therapy for Fluid Overload patients

900+ hospital partnerships[1]

2,500+ clinic[1]

6,500+ employees[1]

11.6B in revenue in 2022[1]

Collaboration Strategy

- Pilot Aquadex to treat adult patients with congestive heart failure in select U.S. markets
- Offer Aquadex to patients across a network of hospitals and outpatient clinics
- Enable accelerated commercial expansion of Aquadex
- Provides DaVita the option to acquire up to 19.9% of Nuwellis

Expected Collaboration Benefits

- Improved patient outcomes and lower long-term cost of care for hospitals and health care system
- Reduce related healthcare costs for providers and payers
- Accelerated Aquadex market penetration
- Provides DaVita with a new therapy offering

1. Used with permission from DaVita

SeaStar Distribution and Licensing Agreement

SeaStar distribution and licensing agreement to offers a new Selective Cytopheretic Device (SCD-PED) for pediatric patients with AKI

77% mortality reduction[1]
At day 60

NO dialysis dependency[2]
At day 60

2x length of stay in ICU for patients with AKI
(8 days vs. 4 days) as ICU patients without AKI[3]

Collaboration Strategy

- Launch market-first SCD-PED device (2024)
- Offer new product to existing Nuwellis pediatric customers
- Develop relationships at new pediatric accounts to support Vivian launch in 2025
- Explore Nuwellis manufacturing viability for SCD
- Strengthen Nuwellis pediatric product portfolio

Expected Collaboration Benefits

- New revenue stream
- Therapeutic diversification
- Strong strategic fit with Vivian

1) Use of the Selective Cytopheretic Device to Support Critically Ill Children Requiring Continuous Renal Replacement Therapy: A Probable Benefit-Risk Assessment Stuart L. Goldstein, Nicholas J. Ollberding, David J. Askenazi, Rajit K. Basu, David T. Selewski, Kelli . Krallman, Lenar Yessayan, H. David HumesmedRxiv 2023.08.22.23294378; doi: https://doi.org/10.1101/2023.08.22.23294378 2) SL Goldstein et al.: The Selective Cytopheretic Device in Children; Kidney International Reports (2021) 3) De Zan F, Amigoni A, Pozzato R, Pettenazzo A, Murer L, Vidal E. Acute Kidney Injury in Critically Ill Children: A Retrospective Analysis of Risk Factors. Blood Purif. 2020;49(1-2):1-7. doi: 10.1159/000502081. Epub 2019 Aug 5. PMID: 31382259.

Market Validation

Real-world testimonials and clinical studies provide meaningful validation for Nuwellis' products.

Ultrafiltration: Positive ROI, clinical and economic benefits

81% reduction in heart failure hospitalizations per year

10-Year, real-world experience with ultrafiltration[1]

AHJ American Heart Journal

Newly published

Abington Hospital Jefferson Health

- Retrospective, single center analysis
- **334 consecutive** acutely decompensated heart failure patients
- Cohort of patients in study were sicker than those in other clinical trials
- Treated with adjustable-rate UF using Aquadex
- Weight loss due to fluid removal
- Unchanged kidney function

HF Hospitalizations

Average 2.14 hospitalizations per year before Aquadex Ultrafiltration

1 Year after Aquadex ultrafiltration
Average 0.4 hospitalizations

Hospital Readmissions

National Average

24% at 30 days[2]

50% at 6 months

12.4% at 30 days

14.9% at 90 days

27.3% at 1 year

Significant quality of life improvement for the patients as well as savings to the healthcare system and to the individual hospitals

1. Watson R et al. *J Cardiac Fail.* 2020; 26(10): s56. 2. Costanzo MR, et al. *JACC.* 2017 May 16;69(19):2428-2445.

nuwellis

Peer-reviewed publication advocates for early clinical application of ultrafiltration in diuretic resistant patients

Diuretic shortcomings leave a gap in clinical care

"The efficacy of diuretics gradually decreases as (heart failure) progresses in a significance subset of patients."

"Diuretic resistance has been a well-known challenge in the care of these patients, and not surprisingly is tied to worse prognosis."



"Extracorporeal Ultrafiltration for Acute Heart Failure"
Cardiorenal Medicine Journal

Pooled data from seven randomized controlled trials of ultrafiltration, 771 patient participants

"Extracorporeal ultrafiltration has emerged as an option to overcome shortcomings of diuretics"

- Predictable, adjustable, and more efficient fluid removal with ultrafiltration compared to diuretics
- Applicability in other clinical settings, such as cardiac surgery, burn and other specialty units
- Potential to expand use of ultrafiltration into outpatient centers and other ambulatory settings

Kazory A, Sgarabotto L, Ronco C: Extracorporeal Ultrafiltration for Acute Heart Failure. Cardiorenal Med 2023;13:1-8. doi: 10.1159/000527204.

nuwellis

With over 16 sites and 80+ patients enrolled, we are in the midst of executing our REVERSE-HF Clinical Study with Aquadex

Ongoing REVERSE-HF randomized controlled trial to support driving ultrafiltration to standard of care



As of December 31, 2023

nuwellis

Growth Strategy

We aim to achieve sustainable expansion and market leadership through strategic growth plans and tactics.

Our strategic growth plan emphasizes four key efforts

We've structured our sales and marketing team to ensure seamless execution

1. **Grow Utilization**
   increase the number of circuits per console
2. **Grow Penetration**
   increase the number of consoles per hospital
3. **Grow number of New Accounts**
4. **Initiate New Indications**

nuwellis®